Genetics

This blog post examines the study by Villoslada and colleagues, which investigated whether serum metabolites can distinguish patients with multiple sclerosis from healthy individuals and identify those at greater risk of relapse or disability progression. Using longitudinal clinical data and UHPLC–mass spectrometry across two independent cohorts, the researchers identified alterations in sphingolipids, phospholipids, amino acids, fatty acids, and steroid hormones. Particular attention is given to sphingomyelin, lysophosphatidylethanolamine, glutamic acid, tryptophan, hydrocortisone, and oxidized fatty acids, highlighting their potential roles in immune activation, myelin damage, membrane remodeling, and neurological deterioration. The article also evaluates the clinical promise and methodological limitations of metabolomics as a source of biomarkers for personalized monitoring in multiple sclerosis.